ARTICLE | Top Story
Merck forms follow-on biologics unit
December 10, 2008 1:21 AM UTC
Merck (NYSE:MRK) said it formed Merck BioVentures to develop follow-on biologics (FOBs). The first candidate in development is MK-2578, a pegylated erythropoietin (EPO) in Phase I testing for anemia, ...